Proteus Digital Health, Inc. announced that it has received $62.5 million in funding from Essex Woodlands Health Ventures, Kaiser Permanente Ventures, Novartis Venture Funds, Oracle Corporation, Otsuka Pharmaceutical Co., Ltd., Sino Portfolio International Ltd, and other investors.

Proteus Biomedical, Inc. announced that it will raise $50,000,000 in an equity round of funding on May 1, 2012. The securities will be issued pursuant to Regulation D.

On the same day, the company raised $17,500,000 from three investors including lead investors Essex Woodlands Health Ventures and Kaiser Permanente Ventures.

On May 1, 2013, Proteus Biomedical, Inc. closed the transaction. The company raised $62,500,000 in its series F round of funding led by a new investor, Oracle Corporation. The company issued preferred stock in the transaction. The second tranche also included participation from existing investors, Novartis Venture Funds, Sino Portfolio International Ltd, Otsuka Pharmaceutical Co., Ltd. and other investors. The company has raised $170,000,000 in funding till date.